Psilera
Wednesday, June 05, 2024
Company Presentation
![CNS/Neurological](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 2
Psilera is a biopharmaceutical company revolutionizing the development of novel serotonergic drugs which provide rapid therapeutic benefit and fewer side effects than conventional treatments. Their world-class scientific and executive team reimagine psychoactive natural products into effective and insurance-backed take-home therapies for psychiatric, addiction, and neurodegenerative disorders. Their proprietary drug discovery engine, Psilera Third Eye, combines novel syntheses of new compounds with an AI-enabled screening platform to design next-generation neurological drugs at the atomic level.
By designing next-generation psychedelics without hallucinogenic effects, these drugs have take-home potential with increased patient access. Psilera’s novel drugs aim to be first and best-in-class for a variety of neurological disorders.
![Psilera](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1751491-1-JPG.png)
Company Website:
https://www.psilera.com/
Lead Product in Development:
PSIL-006 for behavioral variant frontotemporal dementia (bvFTD)
Company HQ City
Tampa
Company HQ State
FL
Company HQ Country
United States
CEO/Top Company Official
Dr. Chris Witowski
Development Phase of Primary Product
Pre-Clinical
Primary Speaker